Skip to content
★ Sign in to follow
SJ

S Jackson

GlaxoSmithKline plc
Total declarations
6
Company
1
▲ Purchases (1 ops.)
€23k
▼ Sales (1 ops.)
€23k

Latest filing published 08 Nov 2019 for GlaxoSmithKline plc, €23k.

Filing timeline

BuySale
S Jackson

Insider track record

Disclosed buys
1
Disclosed sells
1
Signal history

Closed purchases

Market purchases
1

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

S Jackson: trading record in brief

S Jackson appears in our data through filings on GlaxoSmithKline plc shares, published by RNS (LSE). Between 15 April 2019 and 8 November 2019, the trades on record add up to 6 filings.

The open-market side counts 1 purchase for €23k alongside 1 sale for €23k. Sales outweigh purchases by €167. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 4 share grants.

The latest filing, published on 8 November 2019, reports an open-market sale of €23k in GlaxoSmithKline plc. The latest purchase dates back some time: it was published 2,558 days ago, on 8 November 2019. Between a trade and the moment it shows up on RNS (LSE), the median delay is 1 day. Under the UK Market Abuse Regulation, managers have three business days to notify their trades. These figures are compiled from regulatory filings published by RNS (LSE). They describe what insiders did and are not a recommendation.

Companies and markets linked to S Jackson

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations6 total
  • ▼
    SVP, Global Communications & CEO OfficeExecutivesGlaxoSmithKline plc
    20,014 GBP45FCA-NSM
    1,158 shares@ £17.283545.5% of flowLondon Stock Exchange ( XLON)ISIN GB0009252882FCA-NSM:LSE20191108162243_14301521_20200326185148334_23057-0
  • ▲
    SVP, Global Communications & CEO OfficeExecutivesGlaxoSmithKline plc
    19,870 GBP0FCA-NSM
    1,149 shares@ £17.293745.1% of flowLondon Stock Exchange ( XLON)ISIN GB0009252882FCA-NSM:LSE20191108162243_14301521_20200326185148334_23057-1
    Canonical exit: 6 Feb 2020 (T+90)
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    1,462 GBP22FCA-NSM
    89.852 shares@ £16.26953.2% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:LSE20190715181612_14150139_20200326185123935_21358-8
  • ◆
    SVP, Global Communications & CEO OfficeExecutivesGlaxoSmithKline plc
    83 GBP22FCA-NSM
    5 shares@ £16.5220.2% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:LSE20190712163526_14147423_20200326185124019_23194-1
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    941 GBP22FCA-NSM
    57 shares@ £16.5062.1% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:LSE20190712155503_14147391_20200326185124021_23221-3
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    1,744 GBP30FCA-NSM
    112.492 shares@ £15.5009100.0% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:LSE20190416171422_14043624_20200326185042776_11229-9

6 of 6 declarations